How Will Vitasora Scale to 30,000 US Patients with New Privia Partnership?
Vitasora Health is set to scale its AI-powered chronic care services from Hawaii to 10-15 US states, leveraging a new partnership with Privia Health following Evolent Care Partners' divestiture. This expansion targets up to 30,000 patients and promises significant revenue growth in 2026.
- Expansion from Hawaii to 10-15 US mainland states
- Targeting 20,000–30,000 patients in rural Medicare programs
- Annualised recurring revenue forecast of US$12–18 million
- Partnership growth driven by Evolent Care Partners joining Privia Health
- Nationwide rollout expected within 60–90 days
Vitasora’s US Expansion – From Pilot to Multi-State Ambition
Vitasora Health Limited, an Australian digital health innovator, is accelerating its US growth trajectory by expanding its Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services beyond its successful Hawaii pilot. The company announced a significant extension of its agreement with Evolent Care Partners (ECP), now part of Privia Health, to deliver connected care solutions across 10 to 15 mainland states.
This expansion targets a patient population of 20,000 to 30,000 in 2026, focusing on rural communities under Medicare’s value-based care models, including the Medicare Shared Savings Program (MSSP) and Fee-for-Service (FFS). Vitasora’s services aim to improve health outcomes while reducing costs, leveraging its AI-driven platform and clinical expertise.
Strategic Partnership with Privia Health Unlocks Scale
The catalyst for this growth is the recent divestiture of ECP by Evolent Health to Privia Health Group, a physician-led organisation managing approximately 1.5 million lives. Privia’s reputation for supporting independent primary care providers and its high-performing accountable care organisation (ACO) portfolio provide Vitasora with a vastly expanded platform to scale its services nationally.
Vitasora’s CEO, Marjan Mikel, highlighted the Hawaii pilot’s success as a proof point for connected care’s potential, noting that the expanded partnership is pivotal to the company’s path to profitability and revenue growth in 2026. The integration with Privia’s network offers opportunities to collaborate with leadership and leverage additional resources to accelerate adoption.
Financial Outlook and Execution Timeline
The company forecasts annualised recurring revenue between US$12 million and US$18 million, depending on the care mix, with revenue expected to start flowing 30 to 60 days after patient enrolment. The rollout is execution-ready within 60 to 90 days, with meaningful revenue contributions anticipated in the first half of 2026.
Initial milestones include planning and engagement in late 2025, patient enrolments in early 2026, and broader scaling through the year. Beyond 2026, there is significant upside potential tied to Privia’s full portfolio, which could dramatically increase Vitasora’s addressable market.
Innovative Technology and Market Positioning
Vitasora’s offering includes the FDA-approved wheezo® medical device, a unique remote wheeze detection tool integrated into its RPM programs. This technology, combined with its data-driven care management, positions Vitasora at the forefront of chronic disease management in the US healthcare market.
With offices in Melbourne and Los Angeles, Vitasora is well-placed to capitalize on the growing demand for connected care solutions that improve patient outcomes and reduce healthcare costs, particularly in underserved rural areas.
Bottom Line?
Vitasora’s US expansion marks a critical inflection point, setting the stage for transformative growth and deeper integration into America’s value-based care landscape.
Questions in the middle?
- How quickly can Vitasora scale patient enrolments across multiple states?
- What impact will Privia Health’s ownership have on Vitasora’s service adoption and contract terms?
- Can Vitasora sustain and grow its revenue beyond the initial US$12-18 million forecast?
